C Malvy
Overview
Explore the profile of C Malvy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
534
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramon A, Bertrand J, de Martimprey H, Bernard G, Ponchel G, Malvy C, et al.
J Mol Recognit
. 2013 May;
26(7):318-29.
PMID: 23657987
Ewing's sarcoma is a rare, mostly pediatric bone cancer that presents a chromosome abnormality called EWS/Fli-1, responsible for the development of the tumor. In vivo, tumor growth can be inhibited...
2.
de Martimprey H, Vauthier C, Malvy C, Couvreur P
Eur J Pharm Biopharm
. 2008 Nov;
71(3):490-504.
PMID: 18977435
The success of the application of new therapeutic methods based on RNA interfering strategies requires the in vivo delivery of active ODN or siRNA down to the intracellular compartment of...
3.
Pille J, Li H, Blot E, Bertrand J, Pritchard L, Opolon P, et al.
Hum Gene Ther
. 2006 Sep;
17(10):1019-26.
PMID: 17007568
Overexpression of RhoA in cancer indicates a poor prognosis, because of increased tumor cell proliferation and invasion and tumor angiogenesis. We showed previously that anti-RhoA small interfering RNA (siRNA) inhibited...
4.
Toub N, Malvy C, Fattal E, Couvreur P
Biomed Pharmacother
. 2006 Sep;
60(9):607-20.
PMID: 16952435
One way to reach intracellular therapeutic targets in cells consists in the use of short nucleic acids which will bind specifically to on targets thanks to either Watson-Crick base pairing...
5.
Pille J, Denoyelle C, Varet J, Bertrand J, Soria J, Opolon P, et al.
Mol Ther
. 2005 Jan;
11(2):267-74.
PMID: 15668138
Overexpression of RhoA or RhoC in breast cancer indicates a poor prognosis, due to increased tumor cell proliferation and invasion and tumor-dependent angiogenesis. Until now, the strategy of blockage of...
6.
Maksimenko A, Lambert G, Bertrand J, Fattal E, Couvreur P, Malvy C
Ann N Y Acad Sci
. 2004 Jan;
1002:72-7.
PMID: 14751824
We have used structured antisense oligonucleotides (AON), which are protected against extra and intracellular degradation by their internal structure. We have shown that if correctly designed this structure does not...
7.
Laczko I, Bottka S, Toth G, Malvy C, Bertrand J, Hollosi M
Biochem Biophys Res Commun
. 2003 Dec;
313(2):356-61.
PMID: 14684168
The conformational effect of the interaction between various fusogenic peptides and an 18mer single stranded antisense oligonucleotide (ODN), targeted towards the green fluorescent protein mRNA, has been studied by circular...
8.
Bertrand J, Sumbatyan N, Malvy C
Nucleosides Nucleotides Nucleic Acids
. 2003 Oct;
22(5-8):1611-3.
PMID: 14565478
Peptide nucleic acids (PNA) are promising antisense molecule for blocking gene expression in cell culture or in vivo. Nevertheless because they are poor efficient to pass the cellular membrane, it...
9.
Sumbatyan N, Maksimenko A, Gottikh M, Malvy C, Korshunova G
Nucleosides Nucleotides Nucleic Acids
. 2003 Oct;
22(5-8):1077-9.
PMID: 14565348
No abstract available.
10.
Toth J, Boszormenyi I, Majer Z, Laczko I, Malvy C, Hollosi M, et al.
Biochem Biophys Res Commun
. 2002 Jun;
293(1):18-22.
PMID: 12054557
To be efficient in vivo antisense oligonucleotides must reach the targeted cells and then cross the cellular membrane. We propose a two step system where the oligonucleotide is first electrostatically...